Skip to content

NewLink biotech’s latest takeover target?

April 5, 2017

Shares of cancer drug developer NewLink Genetics climbed more than 8 percent at one point Thursday after the stock was upgraded in anticipation of positive data from upcoming product trials.

SunTrust Robinson Humphrey analyst Peter Lawson upgraded NewLink Shares to buy from hold and raised his price target to $30 from $12 per share. The stock closed Thursday priced around $23 per share.

Lawson said NewLink is “well positioned” as a potential takeover target, with its shares up more than 100 percent over the past 3 months.

SunTrust “sees further upside, driven by data and interest in late stage assets,” Lawson said, adding that the stock has rebounded quicker than he expected after suffering a clinical trial failure.

NewLink is one among a handful of companies in the so-called IDO inhibitor space, which is helping further cancer therapies.

Thursday marked the stock’s fourth consecutive day of gains, and it was on pace for its best day since March 2, when shares gained more than 17 percent.

The Iowa-based biopharmaceutical company went public in November 2011 at $7 per share, and it’s now up roughly 234 percent since then.

With Thursday’s gains, the stock is now up more than 120 percent for the year.

http://cnb.cx/2o8wHzc

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: